Vistagen (Nasdaq: VTGN) announced that its intranasal drug candidate fasedienol failed to meet the primary and secondary endpoints in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE